Yilmaz Mesut, Güven Meşe Şermin
Medical Oncology Department, Bakırköy Sadi Konuk Training and Research Hospital, İstanbul, Turkey.
Medical Oncology Department, Yeditepe University Koşuyolu Hospital, İstanbul, Turkey.
J Oncol Pharm Pract. 2020 Oct;26(7):1754-1758. doi: 10.1177/1078155220906011. Epub 2020 Mar 29.
Patients with distant metastatic melanoma has a poor prognosis, with a reported median survival time of six to eight months. In modern era, survival has prolonged with the immunotherapy and targeted therapy options. Potent and selective BRAF inhibitors have been developed that specifically inhibit mutated BRAF over other RAF kinases. Vemurafenib was the first selective tyrosine kinase inhibitor developed to target the V600E allele of BRAF-mutant melanoma.
In this report, we present a case of BRAF-mutant metastatic melanoma, which is being treated with vemurafenib monotherapy with complete response for about seven years.
The patient is still being treated with vemurafenib and radiologic complete response is ongoing for about seven years.
Patients treated with BRAF inhibitors monotherapy had promising response rates and improvement in the progression-free survival and overall survival, but melanoma cells became resistant very quickly, affecting the progression. In this case, we present a case that has permanent response to vemurafenib monotherapy.
远处转移性黑色素瘤患者预后较差，报道的中位生存时间为6至8个月。在现代，免疫疗法和靶向疗法延长了患者的生存期。已开发出强效且选择性的BRAF抑制剂，可特异性抑制突变的BRAF而非其他RAF激酶。维莫非尼是首个开发用于靶向BRAF突变黑色素瘤V600E等位基因的选择性酪氨酸激酶抑制剂。
在本报告中，我们介绍了1例BRAF突变转移性黑色素瘤患者，该患者接受维莫非尼单药治疗，完全缓解约7年。
该患者仍在接受维莫非尼治疗，影像学完全缓解持续约7年。
接受BRAF抑制剂单药治疗的患者有良好的缓解率，无进展生存期和总生存期均有所改善，但黑色素瘤细胞很快产生耐药性，影响病情进展。在此，我们介绍1例对维莫非尼单药治疗有持久反应的病例。
